SRR934957
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 27.496714848883048
- age_years
- 37
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.556
- G2M_CHECKPOINT+0.554
- MYC_TARGETS_V2+0.478
- MITOTIC_SPINDLE+0.429
- MYC_TARGETS_V1+0.424
- NOTCH_SIGNALING+0.384
- WNT_BETA_CATENIN_SIGNALING+0.348
- DNA_REPAIR+0.331
- TGF_BETA_SIGNALING+0.316
- ALLOGRAFT_REJECTION+0.291
Top 10 suppressed
- KRAS_SIGNALING_DN-0.335
- PANCREAS_BETA_CELLS-0.265
- MYOGENESIS-0.233
- CHOLESTEROL_HOMEOSTASIS-0.216
- P53_PATHWAY-0.126
- SPERMATOGENESIS-0.124
- OXIDATIVE_PHOSPHORYLATION-0.119
- APICAL_JUNCTION-0.105
- ESTROGEN_RESPONSE_LATE-0.078
- HYPOXIA-0.076
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934757 | — | — | 0.899 |
| 2 | C67163A8-8A5F-4398-AC65-167218B010CF | — | — | 0.885 |
| 3 | 64F4FE1B-1B96-49CC-B4E9-454D971DB7BC | — | — | 0.883 |
| 4 | BB2A06D9-AF9B-4BF6-8EEC-8F53BD5536B0 | — | — | 0.873 |
| 5 | 8F64E7A6-DEE2-426E-B843-DE4D73ECD667 | — | — | 0.873 |
| 6 | 15838786-D895-4F63-88A9-BDE627AE7958 | — | — | 0.871 |
| 7 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.869 |
| 8 | SRR934775 | — | — | 0.861 |
| 9 | 9EE765BF-748F-41B9-926F-FFD0E8C079E3 | — | — | 0.858 |
| 10 | B2D8ED43-A698-4165-9A96-0ADEEFDA29ED | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.556 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.554 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.478 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.429 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.424 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.384 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.348 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.331 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.316 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.291 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.262 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.202 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.188 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.134 | Inavolisib | — uncovered |
| APOPTOSIS | 0.116 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.114 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.112 | Inavolisib | — uncovered |